Quality of life and pruritus over 52 weeks of apremilast treatment in biologic-naive patients with moderate plaque psoriasis: Results of a real-world, multicenter, prospective study in Greece (APRAISAL)

被引：0
|
作者：
Ioannides, Dimitrios [1 ,2 ]
Tampouratzi, Eleftheria [3 ]
Rigopoulos, Dimitrios [4 ]
Drosos, Alexandros [5 ]
Rovithi, Evangelia [6 ]
Papadavid, Evangelia [7 ]
Papageorgiou, Marina [8 ]
Bassukas, Ioannis [9 ]
Zafiriou, Efterpi [10 ]
Panagakis, Pantelis [11 ]
机构：
[1] Aristotle Univ Thessaloniki, Univ Dept Dermatol 1, Thessaloniki, Greece
[2] Hosp Venereal Skin Dis Thessaloniki, Thessaloniki, Greece
[3] Piraeus Reg Gen Hosp Tzaneio, Dermatol Unit, Piraeus, Greece
[4] Natl Kapodistrian Univ Athens, Dept Dermatol & Venereol 1, Athens, Greece
[5] Gen Hosp Xanthi, Dept Dermatol, Athens, Greece
[6] Venizeleio Pananeio Gen Hosp Heraklion, Dept Dermatol & Venereol, Iraklion, Greece
[7] Natl Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Dept Dermatol & Venereol 2, Athens, Greece
[8] Hosp Venereal & Skin Dis Thessaloniki, State Dept Dermatol, Thessaloniki, Greece
[9] Univ Ioannina, Dept Skin & Venereal Dis, Ioannina, Greece
[10] Univ Gen Hosp Larissa, Univ Clin Dermatol, Larisa, Greece
[11] Andreas Sygros Hosp Athens, Dermatol & Venereol Dept NHS, Athens, Greece
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27506
引用
收藏
页码：AB150 / AB150
页数：1
相关论文
共 50 条
  • [31] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [32] REAL WORLD SKIN CLEARANCE RATES FOR BIOLOGIC TREATMENTS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS FROM A LARGE PROSPECTIVE, OBSERVATIONAL STUDY
    Paul, C.
    Bewley, A.
    Girolomoni, G.
    Reich, K.
    Puig, L.
    Lacour, J. P.
    Augustin, M.
    Naldi, L.
    Menter, A. M.
    Wade, S.
    Viswanathan, H. N.
    Palmer, K.
    Klekotka, P.
    Woolley, J. M.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [33] Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
    Jing Yang
    Kun hu
    Xingyu Li
    Jingjin Hu
    Minjia Tan
    Mi Zhang
    Yehong Kuang
    Chengzhi Lv
    Junchen Chen
    Dermatology and Therapy, 2023, 13 : 477 - 485
  • [34] Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
    Yang, Jing
    Hu, Kun
    Li, Xingyu
    Hu, Jingjin
    Tan, Minjia
    Zhang, Mi
    Kuang, Yehong
    Lv, Chengzhi
    Chen, Junchen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 477 - 485
  • [35] Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
    Feldman, Steven R.
    Zhang, Jingchuan
    Martinez, Diane J.
    Lopez-Gonzalez, Lorena
    Marchlewicz, Elizabeth Hoit
    Shrady, George
    Mendelsohn, Alan M.
    Zhao, Yang
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (02) : 203 - 211
  • [36] A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
    Zagni, Emanuela
    Bianchi, Luca
    Fabbrocini, Gabriella
    Corrao, Salvatore
    Offidani, Annamaria
    Stingeni, Luca
    Costanzo, Antonio
    Pellacani, Giovanni
    Peris, Ketty
    Bardazzi, Federico
    Argenziano, Giuseppe
    Ruffolo, Silvana
    Dapavo, Paolo
    Carrera, Carlo
    Fargnoli, Maria Concetta
    Parodi, Aurora
    Romanelli, Marco
    Malagoli, Piergiorgio
    Talamonti, Marina
    Megna, Matteo
    Raspanti, Massimo
    Paolinelli, Matteo
    Hansel, Katharina
    Narcisi, Alessandra
    Conti, Andrea
    De Simone, Clara
    Chessa, Marco Adriano
    De Rosa, Alina
    Provenzano, Eugenio
    Ortoncelli, Michela
    Moltrasio, Chiara
    Fidanza, Rosaria
    Burlando, Martina
    Tonini, Annalisa
    Gaiani, Francesca Maria
    Simoni, Lucia
    Zullo, Alessandro
    Fiocchi, Martina
    Colombo, Delia
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [37] A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
    Emanuela Zagni
    Luca Bianchi
    Gabriella Fabbrocini
    Salvatore Corrao
    Annamaria Offidani
    Luca Stingeni
    Antonio Costanzo
    Giovanni Pellacani
    Ketty Peris
    Federico Bardazzi
    Giuseppe Argenziano
    Silvana Ruffolo
    Paolo Dapavo
    Carlo Carrera
    Maria Concetta Fargnoli
    Aurora Parodi
    Marco Romanelli
    Piergiorgio Malagoli
    Marina Talamonti
    Matteo Megna
    Massimo Raspanti
    Matteo Paolinelli
    Katharina Hansel
    Alessandra Narcisi
    Andrea Conti
    Clara De Simone
    Marco Adriano Chessa
    Alina De Rosa
    Eugenio Provenzano
    Michela Ortoncelli
    Chiara Moltrasio
    Rosaria Fidanza
    Martina Burlando
    Annalisa Tonini
    Francesca Maria Gaiani
    Lucia Simoni
    Alessandro Zullo
    Martina Fiocchi
    Delia Colombo
    BMC Health Services Research, 21
  • [38] Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis
    Feldman, Steven R.
    Thaci, Diamant
    Gooderham, Melinda
    Augustin, Matthias
    de la Cruz, Claudia
    Mallbris, Lotus
    Buonanno, Marjorie
    Tatulych, Svitlana
    Kaur, Mandeep
    Lan, Shuping
    Valdez, Hernan
    Mamolo, Carla
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (06) : 1162 - +
  • [39] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
    Yarur, A.
    Mantzaris, G.
    Silverberg, M.
    Walshe, M.
    Zezos, P.
    Stein, D.
    Bassel, M.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S400 - S401
  • [40] REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF IN BIOLOGIC-NAIVE ULCERATIVE COLITIS PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Yarur, Andres J.
    Mantzaris, Gerassimos J.
    Silverberg, Mark S.
    Walshe, Margaret
    Zezos, Petros
    Stein, Dara
    Bassel, Marielle
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Radulescu, Gabriela
    Patel, Haridarshan
    Demuth, Dirk
    Bressler, Brian
    GASTROENTEROLOGY, 2019, 156 (06) : S637 - S638
12345